AbbVie’s 8-week hepatitis C drug granted early access in UK
AbbVie, Early Access to Medicines, Hep C
0 Comment
AbbVie’s hepatitis C drug granted early access in UK
Hep C
The future of healthcare: the patient advocate and investor perspectives
Gilead, Hep C, hepatitis C, HIV, Investor perspective, patient centricity, patient engagement, patients, R&D
0 Comment
Examining the views of different stakeholders in the ecosystem supporting drug R&D.
The biggest pharma stories of 2016 so far
Adaptive Pathways, Allergan, AZ, Brexit, Duchenne, Entresto, Gliead, GSK, Hep C, Iqwig, market access, Novartis, Pfizer, pharma, regulators, Theranos
0 Comment
The top 10 pharma milestones of the year to date.
After 2015’s ‘breakthrough’ year for pharma approvals, will 2016 see a dip?
Alzheimer's, FDA approvals, Hep B, Hep C, Hepatitis, market access, MS, pharma
0 Comment
Roche’s MS drug is among major drugs still to come in 2016.
Many millions still untreated – but hep C boom is already over
AbbVie, Gilead, HCV, Hep C, hepatitis C, Sovaldi
0 Comment
Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
Move to eradicate viral hepatitis
Hep C, Hepatitis, hepatitis C, NOhep, WHA, WHO, World Hepatitis Day
0 Comment
NOhep campaign supports action against hepatitis.
